Avacta Share Price (AVCT)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Avacta	LSE:AVCT	London	Ordinary Share	GB00BYYW9G87	ORD 10P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+0.00p	+0.00%	22.30p	243,379	05:30:32

Bid Price		Offer Price	High Price	Low Price	Open Price
22.00p		22.60p	22.30p	22.30p	22.30p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	2.74	-7.89	-9.31		16.7

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), Geiger Count. S (GCS), Port Erin (PEBI)

Avacta (AVCT) Latest News (1)

Avacta News

Date	Time	Source	Headline
17/8/2018	11:30	UKREG	Avacta Group PLC Result of General Meeting
06/8/2018	16:24	UKREG	Avacta Group PLC Holding(s) in Company
30/7/2018	18:17	ALNC	UPDATE: Avacta Raises GBP12 Million To Fund New Drug Development (ALLISS)
30/7/2018	18:08	ALNCF	Alliance News Flash Headline
30/7/2018	18:06	UKREG	Avacta Group PLC Results of Placing and Subscription
30/7/2018	12:48	ALNC	Avacta Sets GBP11.4 Million Share Offer To Fund New Drug Development..
30/7/2018	11:41	UKREG	Avacta Group PLC Proposed Placing and Subscription to raise £11.4m
24/7/2018	11:11	ALNC	Avacta Shares Jump 54% After Cancer Drug Partnership Announced
24/7/2018	07:00	UKREG	Avacta Group PLC Major Therapeutics Co-development Partnership
11/6/2018	10:48	ALNC	Avacta Appoints Ex-Immunocore Boss Eliot Forster As Chairman

More Avacta News

Avacta Takeover Rumours

Avacta (AVCT) Share Charts

1 Year Avacta Chart

1 Month Avacta Chart

Intraday Avacta Chart

Avacta (AVCT) Discussions and Chat

Avacta Forums and Chat

Date	Time	Title	Posts
17/8/2018	13:00	Avacta – Innovative and Disruptive Technologies for Global Health Markets	1,423
10/7/2017	12:54	Avacta – Unique and innovative technology blipping on big pharma’s radar	1,739
13/1/2012	15:28	Avacta Group - Broadening their horizons	1
13/6/2011	12:22	'Best of Palls' - Avacta Group plc	-
25/4/2011	22:50	Avacta with Charts & News	541

Add a New Thread

Avacta (AVCT) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

Date	Subject
18/8/2018 09:20	Avacta Daily Update: Avacta is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 22.30p. Avacta has a 4 week average price of 22.30p and a 12 week average price of 22.30p. The 1 year high share price is 76.50p while the 1 year low share price is currently 22.30p. There are currently 75,009,487 shares in issue and the average daily traded volume is 102,257 shares. The market capitalisation of Avacta is £16,727,115.60. Read Full Thread Reply
15/8/2018 15:00	1i1i1i: At the moment yes, but with bundles of cash in the bank and all the exciting news due then I can only see one direction for the share price here. Read Full Thread Follow Reply
15/8/2018 14:21	jaknife: But the share price is going downwards, not upwards? Read Full Thread Follow Reply
30/7/2018 23:57	escapetohome: A disappointing share price performance Avacta. If you keep this all your bod may be wishing they had read about sustainable financing. Desparate times. Poor confidence in Avacta. A scrounger off shareholders rather than a deliverer of value. FIX IT . AND SOON. Read Full Thread Follow Reply
14/5/2018 21:06	escapetohome: Come on now avacta this is silly, what does this sort of share price say about the running of the company?? Not good. I would get it sorted. Thats my very strong advice indeed. Nudge Nudge Wink Wink!!!! Read Full Thread Follow Reply
29/3/2018 09:42	lantanatony: We need some proper Brokers,capable of supporting the share price. Let's also hope IP Group are the seller as we need them to reduce their influence. But most of all we need a deal with revenue attached. Read Full Thread Follow Reply
18/3/2018 22:13	lantanatony: You may think,that I keep going about the Avacta brokers. But let me point out once again that when they were appointed,Avacta shares were around one pound. Furthermore,as market makers they seem happy to preside over any dramatic drop in the share price ,even on the sale of just a small amount of shares. Yet their Analysts are still predicting a Two pound share price! Talk about a "Toffee shop ". No that's unfair on Toffee Shops! Meanwhile,Avacta keep announcing hopeful information,but no meaningful revenue streams to support them. How could anyone realistically believe that this is a company capable of clinical drug development? Watch out for IP Group loading up Avacta with their next best idea. Then another speculative fundraising. Unfortunately,it's a very sad story. The Avacta Board need to examin their Corporate responsibility. You can not keep telling shareholders that you are going into clinical Development without a creditable structure and of course the finance.......can you? Read Full Thread Follow Reply
10/3/2018 23:04	lantanatony: Why,no statement from the company on the dramatic fall in the share price ? Read Full Thread Follow Reply
11/12/2017 11:06	dec2000: Firstly thanks to biotechgeek for his post which hopefully can start a good conversation. And of course his conclusion that the market will decide is also absolutely correct. He approaches the problem from the point of view of production.. and points out that the three main ways of producing affinity ligands are through synthetic chemistry, phage display and in vivo and goes on to point out that Avacta have “simply” made phage display work with a particular type of protein and they have chosen one that is particularly robust. In my belief this is accurate but also undersells what Avacta have achieved and what they are attempting to achieve. In my belief the production issue is not the most important concern.. what is of real significance is what Avacta are hoping to achieve through the use of this technology. The usefulness of any affinity ligand depends partly on the ligand and also what it is attached to and also what you are trying to use it for. In other words there are horses for courses. Indeed that is what Avacta have said : they are not interested in displacing the role of antibodies generally rather finding some alternatives which work better than antibodies in certain circumstances and they have effectively segmented their market into two : diagnostics and research reagents (the so called RxDx market) and the therapeutics market (the Tx market) . In the RxDx market there is massive competition but there are some advantages that Affimers can bring including ease of developing affinity ligands, small molecular size and stability as well as exquisite sensitivity. Of course they compete against phage-display produced antibodies and others, but they do have advantages themselves and other protein scaffolds have not entered the RxDx territory. The proof of this particular pudding does lie in the eating, but they are generating lots of sales leads and have indeed signed a deal with a top 3 diagnostics company… so it can’t be all bad! The question is - can they carve out for themselves a sensibly sized slice of this particular market? With regard to therapeutics, they have deliberately gone for a differentiated strategy which builds on the differences and advantages of Affimers which seems to me to be reasonable. They are using the ability of Affimers to link with themselves to make multimeric molecules which have significant potential uses as T cell recruiters and combination therapies (which might be more therapeutically effective and also more cost effective), they are using the stability of the cystatin molecule to develop drug conjugates with Glythera (also an IP company) which effectively add, say, a poison to the Affimer molecule to be able to selectively kill unwanted cells such as cancer cells; and they are using the simplicity of the cystatin protein and its ease of expression in cells in gene therapy approaches with Moderna. That sounds to me like a sensible approach and not to be denigrated. Whether it works or not of course is the question and why the shares are currently lowly rated. If any of the above are proved to work then the share price will be much higher. As biotechgeek says : the market will decide. Read Full Thread Follow Reply
08/11/2017 20:54	lantanatony: No support from for the share price from the market or our Brokers even at this low share price. Meanwhile, there seems to be at least one substantial seller about. Therefore, what is the point of our CEO presenting at a Finncap event this month when the hosts are not convinced? I have to ask, what party is insisting on the confidentiality in the deals that Avacta have published? Could it be Avacta are wanting to hide from the deal detail?! Can the whole Big Pharma investing sector be wrong to ignore Avacta? The share price says it all. Read Full Thread Follow Reply
30/11/2016 18:41	dec2000: Yet Finncap yesterday placed a value on AVACTA of 200p in 12 months! Avacta Group PLC (LON:AVCT) Issued With ‘CorporateR17; Rating At FinnCap By Warren Smith / in UK Broker Ratings / on Wednesday, 30 Nov 2016 02:02 PM / 0 Comments Following an update released by analysts at finnCap on Tuesday the broker has now set a ‘CorporateR17; rating on shares of Avacta Group PLC (LON:AVCT) with a price target of 200. On Tuesday finnCap reiterated its target for shares of Avacta Group PLC as ‘CorporateR17; recommending a target price of 200 for investors; potentially meaning there is an increase of 129.75% from Avacta Group PLC’s share price of 87.05. Avacta Group PLC has 68,287,000 shares currently held by shareholders which currently trade around the 87.05 mark which totals Avacta Group PLC’s market capitalisation to 59.44M GBP. 12 Month Share Chart For Avacta Group PLC LON:AVCT In the duration of 12 months Avacta Group PLC’s share price has increased by 0% to 87.05 from 0.00. The business has a 50 day moving average of 89.99 and a 200 day moving average of 95.94 whilst the 52 week high shares of Avacta Group PLC have reached is 134.5 and the 52 week low is 83.02. Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The Company’s segments include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. The Company’s in-house programs include Oncology, which is engaged in developing combination therapies combining multiple immune checkpoint inhibitors by making bi- and tri-specific Affimer constructs, and Blood clotting disorders, which allows Affimer therapeutics to generate the modulate blood clot formation with the potential for anti-thrombotic, as well as wound healing therapies. It focuses on its Affimer technology, which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and develoPment Read Full Thread Follow Reply

Avacta share price data is direct from the London Stock Exchange

add chat code

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:30 V: D:20180818 18:38:30